These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 9302332)

  • 1. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
    de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
    Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Liver injury under tuberculostatic treatment].
    Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
    Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
    Schaberg T; Rebhan K; Lode H
    Eur Respir J; 1996 Oct; 9(10):2026-30. PubMed ID: 8902462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Isoniazid-induced hepatic failure. Report of a case].
    Pereira RM; Tresoldi AT; Hessel G
    Arq Gastroenterol; 2000; 37(1):72-5. PubMed ID: 10962632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
    Parthasarathy R; Sarma GR; Janardhanam B; Ramachandran P; Santha T; Sivasubramanian S; Somasundaram PR; Tripathy SP
    Tubercle; 1986 Jun; 67(2):99-108. PubMed ID: 3775870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
    Girling DJ
    Tubercle; 1978 Mar; 59(1):13-32. PubMed ID: 345572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
    Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
    Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
    Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
    Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
    Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
    Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
    Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
    Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
    Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
    Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
    Tostmann A; Boeree MJ; Aarnoutse RE; de Lange WC; van der Ven AJ; Dekhuijzen R
    J Gastroenterol Hepatol; 2008 Feb; 23(2):192-202. PubMed ID: 17995946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
    Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
    Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver injury during antituberculosis treatment: an 11-year study.
    Døssing M; Wilcke JT; Askgaard DS; Nybo B
    Tuber Lung Dis; 1996 Aug; 77(4):335-40. PubMed ID: 8796249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A clinical investigation of seven patients with pulmonary tuberculosis who developed mixed liver injury during oral anti-tuberculosis treatment].
    Nomi F; Hosaka K; Kurosawa T
    Kekkaku; 2013 Sep; 88(9):647-51. PubMed ID: 24298690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
    Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
    Vu D; Macdonald L
    CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338
    [No Abstract]   [Full Text] [Related]  

  • 20. Antituberculosis drugs and hepatotoxicity.
    Sharma SK
    Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.